Abstract
Background CVD prediction models do not perform well in people with diabetes. We therefore aimed to identify novel predictors for six facets of CVD, (including coronary heart disease (CHD), Ischemic stroke, heart failure (HF), and atrial fibrillation (AF)) in people with T2DM.
Methods Analyses were conducted using the UK biobank and were stratified on history of CVD and of T2DM: 459,142 participants without diabetes or a history of CVD, 14,610 with diabetes but without CVD, and 4,432 with diabetes and a history of CVD. Replication was performed using a 20% hold-out set, ranking features on their permuted c-statistic.
Results Out of the 600+ candidate features, we identified a subset of replicated features, ranging between 32 for CHD in people with diabetes to 184 for CVD+HF+AF in people without diabetes. Classical CVD risk factors (e.g. parental or maternal history of heart disease, or blood pressure) were relatively highly ranked for people without diabetes. The top predictors in the people with diabetes without a CVD history included: cystatin C, self-reported health satisfaction, biochemical measures of ill health (e.g. plasma albumin). For people with diabetes and a history of CVD top features were: self-reported ill health, and blood cell counts measurements (e.g. red cell distribution width). We additionally identified risk factors unique to people with diabetes, consisting of information on dietary patterns, mental health and biochemistry measures. Consideration of these novel features improved risk classification, for example per 1000 people with diabetes 133 CVD and 165 HF cases appropriately received a higher risk.
Conclusion Through data-driven feature selection we identified a substantial number of features relevant for prediction of cardiovascular risk in people with diabetes, the majority of which related to non-classical risk factors such as mental health, general illness markers, and kidney disease.
Competing Interest Statement
NC serves on data safety and monitoring committees of clinical trials sponsored by AstraZeneca. AFS has received funding from New Amsterdam Pharma for unrelated work. None of the other authors of this paper has a financial or personal relationship with other people or organizations that could inappropriately influence or bias the content of the paper.
Funding Statement
KD is supported by a PhD studentship from the National Productivity Investment Fund MRC Doctoral Training Programme (grant no. MR/S502522/1). AFS is supported by BHF grants PG/18/5033837, PG/22/10989, and the UCL BHF Research Accelerator AA/18/6/34223. AFS received additional support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. This work was supported by grant [R01 LM010098] from the National Institutes of Health (USA) and by EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking BigData@Heart grant number 116074, as well as by the UKRI/NIHR Multimorbidity fund Mechanism and Therapeutics Research Collaborative MR/V033867/1 and the Rosetrees Trust. This work is partially supported by Dutch Research Council (628.011.213). This publication is part of the project MyDigiTwin with project number 628.011.213 of the research programme COMMIT2DATA Big Data & Health which is partly financed by the Dutch Research Council (NWO).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research has been conducted using the UK Biobank Resource under application numbers 12113, 24711 and 44972. We are grateful to the UK Biobank participants. UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government, and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government and the British Heart Foundation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Formatting abstract
Data Availability
All data produced in the present study are available upon request to the UK Biobank.
ACRONYMS
- Acronym
- Meaning
- AF
- Atrial fibrillation
- BMI
- Body Mass Index
- CHD
- Coronary heart disease
- CVD
- Cardiovascular disease
- CVD+HF+AF
- Cardiovascular disease including heart failure and/or atrial fibrillation
- DBP
- Diastolic blood pressure
- HDL-C
- High-density lipoprotein cholesterol
- HF
- Heart failure
- LDL-C
- Low-density lipoprotein cholesterol
- MI
- Myocardial infarction
- SBP
- Systolic blood pressure
- T2DM
- Type 2 diabetes
- UKB
- UK Biobank
- w T2DM
- Individuals with T2DM diagnosis but not history of CVD
- w T2DM&CVD
- Individuals with T2DM and a history of CVD
- wo T2DM/CVD
- Individuals with T2DM and a history of CVD
